Brief: Immuron Says It Deprioritized SARS-COV-2 Research
Aug 19 (Reuters) - Immuron Ltd IMC.AX :
* IMMURON UPDATE ON IMM-124E SARS-COV-2 RESEARCH-IMC.AX
* HAS DEPRIORITIZED SARS-COV-2 RESEARCH TO FOCUS ON CLINICAL
DEVELOPMENT OF ADVANCED STAGE THERAPEUTIC DRUG CANDIDATES
Source text for Eikon: ID:nASX7hmS34
Further company coverage: IMC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million